Registration is required to view this event live or on demand. Please complete the form or login below.

Clinical Validation of Cancer Biomarker Signatures using Array Technology

Event Date: September 12, 2012 12 noon Eastern, 9 a.m. Pacific, 4 p.m. GMT, 5 p.m. UK

Sponsored by Affymetrix

The disruption of critical genes is a hallmark of cancer. Identification of these genes is a first step to understanding the disease, but once the genes have been identified, elucidating changes in their expression levels can aid in identifying biomarkers with the potential to predict disease progression and point to appropriate treatments. Approaches to determine the relevance of prospective gene expression signatures for the identification of important disease phenotypes will be discussed. Our webinar panelists, both cancer experts, will describe their research and how they have translated their own discoveries into validated gene expression signatures using arrays.

During the webinar, the speakers will:
  • Describe their experimental approaches to validating genetic signatures
  • Practicalities of clinical trials, such as sample size and availability considerations
  • Address the most critical factors when considering validating gene expression data
  • Answer your questions live on air!
If you have previously registered for this event, please login below:

First Name*
Last Name*
Job Title*
Street Address Line 1*
Street Address Line 2
US State*

(please put NA if not applicable)

Foreign State
US Zip Code*

(please put NA if not applicable)

Foreign Code
Work Phone*
Work Sector*
1. What experimental interest do you have in translational research? (check all that apply)*Global gene expression profiling
Targeted gene expression profiling
microRNA detection and analysis
Gene expression profiling from FFPE sampes
Biomarker validation
Biomarker discovery
Clinical test development
If you checked Other above, please specify:
2. What obstacles are you encountering in performing your translational research? (check all that apply)*Obtaining sufficient quantity of RNA from FFPE sample
Ability to analyze more genes
Lack of available gene expression solutions for FFPE samples
High variability in FFPE gene expression results
Unable to validate research findings in clinical samples
Lack of available gene expression solutions for blood, saliva, or other clinical sample sources
If you chose Other above, please specify:
3. When do you anticipate starting your cancer genomics study? (check one) *Already started
<3 months
3-6 months
6-12 months
>1 year
Not at all
 I understand that by registering to watch this webinar I am agreeing to receive occasional e-mail from Science/AAAS and the sponsor of this webinar, about their respective programs and products. The webcast sponsor and Science/AAAS agree not to rent, sell, exchange, or give your information to any third party without permission*
You must have Javascript and Cookies enabled to access this webcast. Click here for Help.
Please enable Cookies in your browser before registering for the webcast.
*Denotes required.
Brought to you by the Science/AAAS Custom Publishing Office